Kynurenic acid (sodium)

Kynurenic acid sodium, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid sodium is also an agonist of GPR35/CXCR8.

Product Specifications

CAS Number

[2439-02-3]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Apoptosis; CXCR; Endogenous Metabolite; GPR35 ; iGluR

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Kynurenic_acid_sodium.html

Purity

99.82

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

O=C(C1=NC2=CC=CC=C2C(O)=C1)O[Na]

Molecular Formula

C10H6NNaO3

Molecular Weight

211.15

Precautions

H302, H315, H319

References & Citations

[1]Wang J, et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem. 2006 Aug 4;281 (31) :22021-8.|[2]Albuquerque EX, et al. Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges. Biochem Pharmacol. 2013 Apr 15;85 (8) :1027-32.|[3]Małaczewska J, et al. Effect of oral administration of kynurenic acid on the activity of the peripheral blood leukocytes in mice. Cent Eur J Immunol. 2014;39 (1) :6-13.